Involvement of SUR2/Kir6.1 channel in the physiopathology of pulmonary arterial hypertension

• Published in: Frontiers in cardiovascular medicine 2023-01, Vol.9, p.1066047
• Main Authors: Le Ribeuz, Hélène, Masson, Bastien, Dutheil, Mary, Boët, Angèle, Beauvais, Antoine, Sabourin, Jessica, De Montpreville, Vincent Thomas, Capuano, Véronique, Mercier, Olaf, Humbert, Marc, Montani, David, Antigny, Fabrice
• Format: Article
• Language: English
• Subjects: ABCC9; ATP; Cardiovascular Medicine; Life Sciences; metabolism; migration; proliferation; pulmonary arterial tone
• ISSN: 2297-055X; 2297-055X
• DOI: 10.3389/fcvm.2022.1066047

We hypothesized that the ATP-sensitive K channels (KATP) regulatory subunit (ABCC9) contributes to PAH pathogenesis. gene encodes for two regulatory subunits of KATP channels: the SUR2A and SUR2B proteins. In the KATP channel, the SUR2 subunits are associated with the K channel Kir6.1. We investigated how the SUR2/Kir6.1 channel contributes to PAH pathogenesis and its potential as a therapeutic target in PAH. Using , and approaches, we analyzed the localization and expression of SUR2A, SUR2B, and Kir6.1 in the pulmonary vasculature of controls and patients with PAH as in experimental pulmonary hypertension (PH) rat models and its contribution to PAH physiopathology. Finally, we deciphered the consequences of activation of SUR2/Kir6.1 in the monocrotaline (MCT)-induced PH model. We found that SUR2A, SUR2B, and Kir6.1 were expressed in the lungs of controls and patients with PAH and MCT-induced PH rat models. Organ bath studies showed that SUR2 activation by pinacidil induced relaxation of pulmonary arterial in rats and humans. experiments on human pulmonary arterial smooth muscle cells and endothelial cells (hPASMCs and hPAECs) in controls and PAH patients showed decreased cell proliferation and migration after SUR2 activation. We demonstrated that SUR2 activation in rat right ventricular (RV) cardiomyocytes reduced RV action potential duration by patch-clamp. Chronic pinacidil administration in control rats increased heart rate without changes in hemodynamic parameters. Finally, pharmacological activation of SUR2 on MCT and Chronic-hypoxia (CH)-induced-PH rats showed improved PH. We showed that SUR2A, SUR2B, and Kir6.1 are presented in hPASMCs and hPAECs of controls and PAH patients. SUR2 activation reduced the MCT-induced and CH-induced PH phenotype, suggesting that SUR2 activation should be considered for treating PAH.